Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis.

Kalil AC, Florescu MC, Grant W, Miles C, Morris M, Stevens RB, Langnas AN, Florescu DF.

Expert Rev Anti Infect Ther. 2014 Jul;12(7):881-96. doi: 10.1586/14787210.2014.917046. Epub 2014 May 29.

PMID:
24869718
2.

Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.

Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA.

J Heart Lung Transplant. 2008 Aug;27(8):835-42. doi: 10.1016/j.healun.2008.05.013. Epub 2008 Jun 30. Review.

PMID:
18656795
4.

Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.

Bonaros N, Dunkler D, Kocher A, Imhof M, Grimm M, Zuckermann A, Wolner E, Laufer G.

J Heart Lung Transplant. 2006 Sep;25(9):1154-63. Epub 2006 Aug 8.

PMID:
16962480
5.

Interleukin 2 receptor antagonists for kidney transplant recipients.

Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003897. doi: 10.1002/14651858.CD003897.pub3. Review.

PMID:
20091551
6.

Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.

Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C.

JAMA. 2012 Mar 21;307(11):1169-77. doi: 10.1001/jama.2012.316.

PMID:
22436957
7.

Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.

Schadde E, D'Alessandro AM, Knechtle SJ, Odorico J, Becker Y, Pirsch J, Sollinger H, Fernandez LA.

Transpl Int. 2008 Jul;21(7):625-36. doi: 10.1111/j.1432-2277.2008.00642.x. Epub 2008 Apr 4.

8.

Epidemiology and risk factors for late infection in solid organ transplant recipients.

Cervera C, Fernández-Ruiz M, Valledor A, Linares L, Antón A, Ángeles Marcos M, Sanclemente G, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Pumarola T, Moreno A.

Transpl Infect Dis. 2011 Dec;13(6):598-607. doi: 10.1111/j.1399-3062.2011.00646.x. Epub 2011 Apr 27.

PMID:
21535336
9.

Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.

Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.

Transplantation. 2009 Oct 15;88(7):904-10. doi: 10.1097/TP.0b013e3181b724a5.

PMID:
19935462
10.

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.

Couchoud-Heyer C.

Cochrane Database Syst Rev. 2007 Jul 18;(4):CD001320. Review.

PMID:
17636667
11.

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.

Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC.

Transplantation. 2004 Jan 27;77(2):166-76.

PMID:
14742976
12.

Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.

Helfrich M, Ison MG.

Transpl Infect Dis. 2015 Oct;17(5):627-36. doi: 10.1111/tid.12428. Epub 2015 Sep 26. Review.

PMID:
26228653
13.

CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.

Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A.

Clin Transplant. 2008 Jan-Feb;22(1):89-97. doi: 10.1111/j.1399-0012.2007.00750.x.

PMID:
18217909
14.

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.

Morgan RD, O'Callaghan JM, Knight SR, Morris PJ.

Transplantation. 2012 Jun 27;93(12):1179-88. doi: 10.1097/TP.0b013e318257ad41. Review.

PMID:
22660659
15.

Infectious complications of antilymphocyte therapies in solid organ transplantation.

Issa NC, Fishman JA.

Clin Infect Dis. 2009 Mar 15;48(6):772-86. doi: 10.1086/597089. Review.

16.
17.

Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.

Lim WH, Chang SH, Chadban SJ, Campbell SB, Dent H, Russ GR, McDonald SP.

Transplantation. 2009 Nov 27;88(10):1208-13. doi: 10.1097/TP.0b013e3181bb4339.

PMID:
19935375
18.
19.

A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant.

Florescu DF, Qiu F, Schmidt CM, Kalil AC.

Clin Infect Dis. 2014 Mar;58(6):785-803. doi: 10.1093/cid/cit945. Epub 2014 Jan 2.

20.
Items per page

Supplemental Content

Write to the Help Desk